Geraghty james (37 Ergebnisse)

Hardback. Zustand: Very Good. Advances in medicine have made possible better treatments for widespread, familiar human illnesses like cancer, diabetes, and heart disease. Yet there are thousands of much less common diseases, most of genetic origin, each classed as rare because it afflicts only a small number of people. These patient groups were long ignored by a pharmaceutical industry that judged them too small to provide a return on the investment needed to develop an effective remedy. Yet these orphaned diseases collectively caused misery and expense, often far greater than did more common ailments, for tens of millions of individuals and their families. Forty years ago, a revolution that transformed the prospects of patients with rare diseases was lit by three sparks. The passage of the 1983 U.S. Orphan Drug Act resulted from public pressure brought by rare disease patients, their families, and advocates. The AIDS epidemic triggered additional activism, compounded when patients with the rare disease hemophilia became HIV-positive after infusion of tainted blood products. And the third spark was the emergence in the early 1980s of biotechnology companies like Genentech, Amgen, and Biogen employing then-new genetic engineering instead of conventional approaches to pharmaceutical development. Soon after, Genzyme became the first company to develop a treatment for a rare genetic disorder, Gaucher disease, which would come to transform the industry. Jim Geraghty has been a passionate participant in the orphan drug revolution since its inception--a leader in the field as a strategy consultant, biotechnology executive, and venture entrepreneur. His book is in part a history, with eyewitness accounts of advances as they occurred and portraits of the pioneering scientists and physicians, tireless activists, and visionary business leaders who made the revolution happen. And it tells deeply personal stories of patients and parents willing to risk new, untried therapies. But Geraghty also uses his exceptional experience and vantage point to look forward to the immense promise of the newest technologies like gene therapy and gene editing for the treatment of patients today and tomorrow. He concludes with thoughtful consideration of important questions. Why do drugs to treat orphan diseases cost so much? How can we ensure they are affordable? How can their effectiveness be responsibly assessed? And how can access to them be expanded internationally? This book graphically and poignantly illustrates how far an important healthcare revolution has come and reminds us that if not nurtured, it could end before its immense promise has been fulfilled.…

Hardcover. Zustand: Very Good. No Jacket. May have limited writing in cover pages. Pages are unmarked. ~ ThriftBooks: Read More, Spend Less.

Hardcover. Zustand: As New. No Jacket. Pages are clean and are not marred by notes or folds of any kind. ~ ThriftBooks: Read More, Spend Less.

paperback. Zustand: Fine. Sealed in original plastic but plastic is ripped.

paperback. Zustand: New.

PAP. Zustand: New. New Book. Shipped from UK. Established seller since 2000.

PAP. Zustand: New. New Book. Shipped from UK. Established seller since 2000.

Hardcover. Zustand: Very Good. Hardcover (no dust jacket; printed boards). Very good condition. From the offices of a world-leading nuclear medicine research establishment. With 43 figures, 18 in colour. Spine ends and boards' corners are bumped and scuffed, and a couple of other minor scuffs to spine. Pages are sound and clear. TA. Used.…

Zustand: New. In English.

HRD. Zustand: New. New Book. Shipped from UK. Established seller since 2000.

HRD. Zustand: New. New Book. Shipped from UK. Established seller since 2000.

HRD. Zustand: New. New Book. Shipped from UK. Established seller since 2000.

HRD. Zustand: New. New Book. Shipped from UK. Established seller since 2000.

Zustand: very good. Gut/Very good: Buch bzw. Schutzumschlag mit wenigen Gebrauchsspuren an Einband, Schutzumschlag oder Seiten. / Describes a book or dust jacket that does show some signs of wear on either the binding, dust jacket or pages.

Hardcover. Zustand: Brand New. 264 pages. 9.37x6.38x0.94 inches. In Stock.

Zustand: New. In English.

Zustand: New.

Hardcover. Zustand: Very Good. Zustand des Schutzumschlags: Very Good. 1st Edition. The jacket of the spine is heavily sun faded, otherwise nearly fine.

Zustand: New. 2022. Hardcover. . . . . . Books ship from the US and Ireland.

Paperback. Zustand: Brand New. 1st edition. 265 pages. 9.00x6.00x0.75 inches. In Stock.

Zustand: New. This is a Brand-new US Edition. This Item may be shipped from US or any other country as we have multiple locations worldwide.

Buch. Zustand: Neu. Neuware - Advances in medicine have made possible better treatments for widespread, familiar human illnesses like cancer, diabetes, and heart disease. Yet there are thousands of much less common diseases, most of genetic origin, each classed as 'rare' because it afflicts only a small number of people. These patient groups were long ignored by a pharmaceutical industry that judged them too small to provide a return on the investment needed to develop an effective remedy. Yet these 'orphaned' diseases collectively caused misery and expense, often far greater than did more common ailments, for tens of millions of individuals and their families. Forty years ago, a revolution that transformed the prospects of patients with rare diseases was lit by three sparks. The passage of the 1983 U.S. Orphan Drug Act resulted from public pressure brought by rare disease patients, their families, and advocates. The AIDS epidemic triggered additional activism, compounded when patients with the rare disease hemophilia became HIV-positive after infusion of tainted blood products. And the third spark was the emergence in the early 1980s of biotechnology companies like Genentech, Amgen, and Biogen employing then-new genetic engineering instead of conventional approaches to pharmaceutical development. Soon after, Genzyme became the first company to develop a treatment for a rare genetic disorder, Gaucher disease, which would come to transform the industry. Jim Geraghty has been a passionate participant in the orphan drug revolution since its inception--a leader in the field as a strategy consultant, biotechnology executive, and venture entrepreneur. His book is in part a history, with eyewitness accounts of advances as they occurred and portraits of the pioneering scientists and physicians, tireless activists, and visionary business leaders who made the revolution happen. And it tells deeply personal stories of patients and parents willing to risk new, untried therapies. But Geraghty also uses his exceptional experience and vantage point to look forward to the immense promise of the newest technologies like gene therapy and gene editing for the treatment of patients today and tomorrow. He concludes with thoughtful consideration of important questions. Why do drugs to treat orphan diseases cost so much How can we ensure they are affordable How can their effectiveness be responsibly assessed And how can access to them be expanded internationally This book graphically and poignantly illustrates how far an important healthcare revolution has come and reminds us that if not nurtured, it could end before its immense promise has been fulfilled.…

Zustand: NEW.

Soft cover. Zustand: As New.

Zustand: New. This is a Brand-new US Edition. This Item may be shipped from US or any other country as we have multiple locations worldwide.

Taschenbuch. Zustand: Neu. The Present State of Ireland, | and the only means of preserving her to the Empire, considered. : In a letter to the Marquis Cornwallis. | James Geraghty | Taschenbuch | 56 S. | Englisch | 2017 | hansebooks | EAN 9783337101947 | Verantwortliche Person für die EU: Hansebooks GmbH, Trakehner Weg 52, 22844 Norderstedt, gb[at]hansebooks[dot]com | Anbieter: preigu. …

Zustand: New. &Uumlber den AutorA widely recognized leader in the rare disease field, Jim Geraghty has been a director or chair of seven NASDAQ-listed biotech companies. He s worked on orphan drugs for more than 40 yearsDLas a strategy consultant, a .

Zustand: Used. pp. 207.

Taschenbuch. Zustand: Neu. Druck auf Anfrage Neuware - Printed after ordering - Liver Metastasis: Biology, Diagnosis and Treatment offers a comprehensive overview of liver metastasis by providing a collection of pivotal contributions from an international faculty. A wide range of topics are presented, with each contributor focusing on his own area of expertise to provide the latest techniques as well as valuable insights based on a wealth of experience. Epidemiological and biological aspects are discussed, diagnostic and staging problems are reported, and all treatment modalities are analysed including gene therapy, immunotherapy and palliative care. The standard approaches to diagnosis and therapy are examined whilst new and future trends are reported on and explored. Of interest to both specialists and postgraduates in the fields of oncology and gastroenterology this book will also be of interest to researchers in internal medicine.…

Hardcover. IX, 207 p.; 43 fig. Very good condition. Reading pages are very clean and without marks. Minimal signs of storage and use. Still very good copy. 9783540760757 Sprache: Englisch Gewicht in Gramm: 1000.